Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)

An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.

Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ: MLTX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Switzerland based MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.

MoonLake Immunotherapeutics' sole drug candidate is sonelokimab ("SLK"), which was developed primarily for the treatment of hidradenitis suppurativa ("HS"). Central to SLK's commercial prospects was its ability to demonstrate efficacy in HS comparable or superior to Union Chimique Belge's BIMZELX, a U.S. Food & Drug Administration-approved monoclonal antibody for the same indication, the complaint alleges.

On September 28, 2025, MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 16-week results from its Phase 3 VELA program which showed that SLK failed to demonstrate competitive efficacy relative to BIMZELX.

Shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) declined from $62.75 per share on September 26, 2025, to as low as $5.95 per share on September 29, 2025.

According to the complaint the plaintiff alleges on behalf of purchasers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common shares between March 10, 2024 and September 29, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 10, 2024 and September 29, 2025, the defendants made false and/or misleading statements and/or failed to disclose that SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F), that SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX, and that SLK's distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy.

Those who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.